WND ranks 18th among nation's biomedical parks

The 2024 China Biomedical Industrial Park Competitiveness Evaluation and Analysis Report is released on Oct 31. [Photo/WeChat account: xinwu_wx]

The 2024 China Biomedical Industrial Park Competitiveness Evaluation and Analysis Report was recently released, revealing WND's record-breaking 18th spot on the list.

In 2023, WND's biomedical industry continued to lead the charge in Wuxi, with its industrial scale exceeding 100 billion yuan ($14.09 billion) for the first time, representing 52.3 percent of the city's total.

By the end of 2023, WND had accumulated 56 Class III medical devices and 477 Class II medical devices that have been approved for registration, with a total of 155 clinical trials conducted. Sunvozertinib, an innovative drug from Dizal Pharma, has received the first approval of a locally originated drug in Wuxi over a decade, while four products from biomedical companies such as Nutricia and Hengyi Health Technology have received certificates for food for special medical purposes.

In an effort to enhance the comprehensive competitiveness of its biomedical industry, WND is set to optimize support in terms of policies, capital, platforms, and lands.